Kronos Bio, Inc. Stock Price

NasdaqCM:KRON Community·US$52.9m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create a narrative

KRON Share Price Performance

US$0.88

-0.04 (-4.34%)

US$0.88

-0.04 (-4.34%)

US$0.88

Wed, 12 Nov 25

Share Pricen/a

KRON Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Snowflake Analysis

Flawless balance sheet and slightly overvalued.

2 Risks

0 Rewards

View Full Analysis

Kronos Bio, Inc. Key Details

Last Reported Earnings

Mar 31, 2025

Next Reporting Earnings

n/a

: -1.06
: 100.00%
: -701.53%
: 0%

View Full Analysis

About KRON

Founded: 2017
Employees: 8
CEO: Deborah Knobelman
WebsiteView website: www.kronosbio.com

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT inhibitor, which is in preclinical development for the treatment of Sjogren’s disease. The company was incorporated in 2017 and is headquartered in San Mateo, California.